Literature DB >> 22901109

Advanced imaging applications for locally advanced cervical cancer.

Janjira Petsuksiri1, Atthapon Jaishuen, Pittayapoom Pattaranutaporn, Yaowalak Chansilpa.   

Abstract

Advanced imaging approaches (computed tomography, CT; magnetic resonance imaging, MRI; 18F-fluorodeoxyglucose positron emission tomography, FDG PET) have increased roles in cervical cancer staging and management. The recent FIGO (International Federation of Gynecology and Obstetrics) recommendations encouraged applications to assess the clinical extension of tumors rather than relying on clinical examinations and traditional non-cross sectional investigations. MRI appears to be better than CT for primary tumors and adjacent soft tissue involvement in the pelvis. FDG-PET/CT has increased in usage with a particular benefit for whole body evaluation of tumor metabolic activity. The potential benefits of advanced imaging are assisting selection of treatment based upon actual disease extent, to adequately treat a tumor with minimal normal tissue complications, and to predict the treatment outcomes. Furthermore, sophisticated external radiation treatment and brachytherapy absolutely require advanced imaging for target localization and radiation dose calculation.

Entities:  

Mesh:

Year:  2012        PMID: 22901109     DOI: 10.7314/apjcp.2012.13.5.1713

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  2 in total

Review 1.  Implications of the revised cervical cancer FIGO staging system.

Authors:  Neerja Bhatla; Seema Singhal; Ekta Dhamija; Sandeep Mathur; Jayashree Natarajan; Amita Maheshwari
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

2.  Dosimetric Comparison between Three-Dimensional Magnetic Resonance Imaging-Guided and Conventional Two-Dimensional Point A-Based Intracavitary Brachytherapy Planning for Cervical Cancer.

Authors:  Juan Ren; Wei Yuan; Ruihua Wang; Qiuping Wang; Yi Li; Chaofan Xue; Yanli Yan; Xiaowei Ma; Li Tan; Zi Liu
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.